Nuclear pseudoinclusion is associated with BRAF V600E mutation: Analysis of nuclear features in papillary thyroid carcinoma

被引:0
|
作者
Harahap, Agnes Stephanie [1 ,2 ]
Khoirunnisa, Dina [3 ]
Salinah [1 ]
Ham, Maria Francisca [1 ,2 ]
机构
[1] Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Fac Med, Dept Anat Pathol, Jl Salemba Raya 6, Jakarta 14320, Indonesia
[2] Univ Indonesia, Indonesian Med Educ & Res Inst, Fac Med, Human Canc Res Ctr, Jakarta 14320, Indonesia
[3] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Fac Med, Bandung 40161, Indonesia
关键词
Thyroid neoplasm; PTC; BRAF V600E; RAS; Nuclei;
D O I
10.1016/j.anndiagpath.2024.152434
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Papillary thyroid carcinoma (PTC) is the most prevalent thyroid neoplasm, classified into BRAF-like and RAS-like subtypes. Nuclear alterations serve as a diagnostic criterion of PTC and are fully manifested in BRAF-like. This single-center retrospective study aimed to assess the different presentation of nuclear features in 40 samples of BRAFV600E- and 40 samples of RAS-mutated PTCs using both bivariate and multivariate analytic approaches. Nuclear features are evaluated histologically using the 3-point and 8-point scoring systems established by the World Health Organization and the Asian Thyroid Working Group, respectively. We found the presence of membrane irregularities, nuclear elongation, nuclear groove, sickle-shaped nuclei, nuclear pseudoinclusion, and higher nuclear scores are significantly associated with BRAFV600E. Multivariate analysis showed that nuclear pseudoinclusion is predictive for the presence of BRAFV600E mutation (OR = 10.97, 95%CI = 2.81-42.96, p = 0.001) and has sensitivity of 55 %, specificity of 92.5 %, positive predictive value of 88 %, negative predictive value of 67.3 %, and accuracy of 73.8 %. There are various pathways and protooncogenes associated with the development of thyroid neoplasm. This study found significant differences in nuclear features between BRAFV600E and RAS-mutated PTC. BRAFV600E tend to display florid nuclear features, whereas the RAS- mutation is associated with subtle nuclear features. These findings emphasize the distinct cytological profiles of BL and RL PTC, reinforcing the need for precise subtyping to guide tailored management.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma
    Sun, Jian
    Zhang, Jing
    Lu, Junliang
    Gao, Jie
    Lu, Tao
    Ren, Xinyu
    Duan, Huanli
    Liang, Zhiyong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15072 - 15078
  • [32] Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
    Gandolfi, Greta
    Sancisi, Valentina
    Piana, Simonetta
    Ciarrocchi, Alessia
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (05) : 1001 - 1011
  • [33] Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma
    Zhu, Xiaoli
    Luo, Yanli
    Bai, Qianming
    Lu, Yongming
    Lu, Yiqiong
    Wu, Lijing
    Zhou, Xiaoyan
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2016, 100 (01) : 236 - 241
  • [34] BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
    Lai, Hon-Fan
    Hang, Jen-Fan
    Kuo, Po-Chung
    Kuo, Chin-Sung
    Yao, San-Fan
    Chen, Jui-Yu
    Lee, Chen-Hsen
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (05) : 3495 - 3501
  • [35] Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma
    Kim, Seo Ki
    Woo, Jung-Woo
    Lee, Jun Ho
    Park, Inhye
    Choe, Jun-Ho
    Kim, Jung-Han
    Kim, Jee Soo
    ENDOCRINE-RELATED CANCER, 2016, 23 (01) : 27 - 34
  • [36] Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma
    Chen, Dan
    Qi, Wenjing
    Zhang, Pengxin
    Zhang, Yunkun
    Liu, Ye
    Guan, Hongwei
    Wang, Lifen
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (02) : 303 - 307
  • [37] Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study
    Virk, Renu K.
    Theoharis, Constantine G. A.
    Prasad, Avinash
    Chhieng, David
    Prasad, Manju L.
    VIRCHOWS ARCHIV, 2014, 464 (04) : 435 - 442
  • [38] BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
    Hon-Fan Lai
    Jen-Fan Hang
    Po-Chung Kuo
    Chin-Sung Kuo
    San-Fan Yao
    Jui-Yu Chen
    Chen-Hsen Lee
    Annals of Surgical Oncology, 2024, 31 : 3495 - 3501
  • [39] DETERMINATION OF BRAF V600E MUTATIONS IN PATIENTS WITH PAPILLARY THYROID CARCINOMA
    Pavlova, Anastasia
    Kulyash, Alexey
    Bubnova, Ludmila
    Pavlova, Irma
    HLA, 2020, 95 (04) : 363 - 363
  • [40] Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma DISCUSSION
    Yip, Linwah
    Zagzag, Jonathan
    Moo-Young, Tricia A.
    Nilubol, Naris
    Sippel, Rebecca S.
    Solorzano, Carmen C.
    Parangi, Sareh
    SURGERY, 2013, 154 (06) : 1204 - 1205